FDAnews
www.fdanews.com/articles/130550-roche-halts-taspoglutide-dosing-due-to-hypersensitivity-issues

Roche Halts Taspoglutide Dosing Due to Hypersensitivity Issues

September 24, 2010
Roche is halting dosing in Phase III trials of its diabetes drug taspoglutide after higher-than-expected discontinuations due to gastrointestinal tolerability and hypersensitivity reactions. Roche subsidiary Genentech is working to identify the root cause of the reactions and is considering changing the drug’s formulation, Genentech spokesman Terry Hurley said.
Clinical Trials Advisor